Fundación Investigación Clínico de Valencia
Welcome,         Profile    Billing    Logout  
 2 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
A
EMERALD, NCT05001737 / 2021-001577-24: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Active, not recruiting
3
41
Europe, Canada, Japan, US, RoW
Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO)
Swedish Orphan Biovitrum
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
06/24
09/25
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Active, not recruiting
2
300
US
AVD-104, Avacincaptad
Aviceda Therapeutics, Inc.
Geographic Atrophy of the Macula, Macular Degeneration
09/25
09/26
NCT06220526: Comparing Menghini-type Needle and Franseen-type Needle in EBUS-TBNA for Sarcoidosis

Recruiting
N/A
128
Canada
endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
University Health Network, Toronto
Suspected Sarcoidosis
02/26
02/26
PELICAN, NCT06423300: Evaluation of the Patellar LIFT System for Subjects with Patellofemoral Cartilage Degeneration

Recruiting
N/A
245
US
LIFT Implant, Tibial Tubercle Osteotomy
ZKR Orthopedics Inc
Patellofemoral Osteoarthritis
09/27
09/31
mbNF, NCT05617495: Mindfulness-Based fMRI Neurofeedback for Depression

Recruiting
N/A
90
US
Mindfulness + fMRI Neurofeedback, Mindfulness-based Real-time fMRI Neurofeedback
Columbia University, National Institute of Mental Health (NIMH)
Depression in Adolescence, Rumination
05/26
06/26
NCT05520736: Mhealth Supported Bundle to Improve Vaccination Completion

Active, not recruiting
N/A
2855
RoW
Appointment reminders, motivational interviewing and targeted vaccine drives
Indiana University, National Center for Advancing Translational Sciences (NCATS)
Vaccination
09/25
09/25
HARMONY, NCT03769415: Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Recruiting
N/A
500
US
Intrinsic Subtyping of Primary Breast Cancer
UNC Lineberger Comprehensive Cancer Center, Veracyte, Inc., Breast Cancer Research Foundation
Breast Cancer
12/30
12/30
Cervantes, Andrés
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT04259450 / 2019-003296-19: Study to Assess AFM24 in Advanced Solid Cancers

Completed
1/2
85
Europe, US, RoW
14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24
Affimed GmbH
Advanced Solid Tumor
07/23
06/24
AFM24-102, NCT05109442 / 2021-000707-20: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH, Affimed GmbH
Advanced Solid Tumor
02/25
11/25
LEGACY-2, NCT04015466: Advanced GC Multi-omic Characterization in EU and CELAC Populations

Completed
N/A
800
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Gastric Cancer
12/23
12/23
LEGACY-3, NCT04019808: Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population

Completed
N/A
800
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Gastric Cancer
12/23
12/23
ALFAOMEGA, NCT04120935: Master Observational Trial

Recruiting
N/A
3000
Europe
Observation
IFOM ETS - The AIRC Institute of Molecular Oncology
Colorectal Cancer
07/25
12/25
NCT02636855: Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

Completed
N/A
9122
Europe, Canada, US
Adaptimmune
Solid and Hematological Malignancies
06/24
06/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
A
EMERALD, NCT05001737 / 2021-001577-24: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Active, not recruiting
3
41
Europe, Canada, Japan, US, RoW
Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO)
Swedish Orphan Biovitrum
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
06/24
09/25
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Active, not recruiting
2
300
US
AVD-104, Avacincaptad
Aviceda Therapeutics, Inc.
Geographic Atrophy of the Macula, Macular Degeneration
09/25
09/26
NCT06220526: Comparing Menghini-type Needle and Franseen-type Needle in EBUS-TBNA for Sarcoidosis

Recruiting
N/A
128
Canada
endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
University Health Network, Toronto
Suspected Sarcoidosis
02/26
02/26
PELICAN, NCT06423300: Evaluation of the Patellar LIFT System for Subjects with Patellofemoral Cartilage Degeneration

Recruiting
N/A
245
US
LIFT Implant, Tibial Tubercle Osteotomy
ZKR Orthopedics Inc
Patellofemoral Osteoarthritis
09/27
09/31
mbNF, NCT05617495: Mindfulness-Based fMRI Neurofeedback for Depression

Recruiting
N/A
90
US
Mindfulness + fMRI Neurofeedback, Mindfulness-based Real-time fMRI Neurofeedback
Columbia University, National Institute of Mental Health (NIMH)
Depression in Adolescence, Rumination
05/26
06/26
NCT05520736: Mhealth Supported Bundle to Improve Vaccination Completion

Active, not recruiting
N/A
2855
RoW
Appointment reminders, motivational interviewing and targeted vaccine drives
Indiana University, National Center for Advancing Translational Sciences (NCATS)
Vaccination
09/25
09/25
HARMONY, NCT03769415: Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Recruiting
N/A
500
US
Intrinsic Subtyping of Primary Breast Cancer
UNC Lineberger Comprehensive Cancer Center, Veracyte, Inc., Breast Cancer Research Foundation
Breast Cancer
12/30
12/30
Cervantes, Andrés
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT04259450 / 2019-003296-19: Study to Assess AFM24 in Advanced Solid Cancers

Completed
1/2
85
Europe, US, RoW
14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24
Affimed GmbH
Advanced Solid Tumor
07/23
06/24
AFM24-102, NCT05109442 / 2021-000707-20: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH, Affimed GmbH
Advanced Solid Tumor
02/25
11/25
LEGACY-2, NCT04015466: Advanced GC Multi-omic Characterization in EU and CELAC Populations

Completed
N/A
800
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Gastric Cancer
12/23
12/23
LEGACY-3, NCT04019808: Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population

Completed
N/A
800
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Gastric Cancer
12/23
12/23
ALFAOMEGA, NCT04120935: Master Observational Trial

Recruiting
N/A
3000
Europe
Observation
IFOM ETS - The AIRC Institute of Molecular Oncology
Colorectal Cancer
07/25
12/25
NCT02636855: Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

Completed
N/A
9122
Europe, Canada, US
Adaptimmune
Solid and Hematological Malignancies
06/24
06/24

Download Options